SGC Board of Directors (Phase III)

Prof. Markus Grütter (Chair)

University Professor, Biochemistry

Vice Dean of Research and Planning, Medical Faculty
University of Zurich, Switzerland
Role on Board: Chair
Nominating organisation: Independent

Dr. Tim Willson

Director of Chemical Biology, GSK
Role on Board: Director
Nominating organisation: GSK

Dr. Hans Widmer

Executive Director, Academic Liaison and Knowledge Management, Novartis Institutes for BioMedical Research
Role on Board: Director
Nominating organisation: Novartis

Dr. Mark Bunnage

Vice President, Head of Chemistry and Biotherapeutics Research, Pfizer
Role on Board: Director
Nominating organisation: Pfizer

Dr. Cindy Bell

Executive Vice President, Corporate Development, Genome Canada
Role on Board: Director
Nominating organisation: Genome Canada

Dr. Stephen Burley

Senior Vice President Research, Eli Lilly
Role on Board: Director
Nominating organisation: Eli Lilly

Dr. Michael Dunn

Head of Molecular and Physiological Sciences, Wellcome Trust
Role on Board: Director
Nominating organisation: Wellcome Trust

Dr. Paul Lasko

Scientific Director, CIHR-Institute of Genetics IRSC-Institut de génétique
Role on Board: Director
Nominating organisation: CIHR

Ms Alison Barr or Mr Craig Fowler or Ms Jane Kirkwood

Director - Research Branch, Ontario Ministry of Research and Innovation
Role on Board: Observer
Nominating organisation: OMRI

Dr. Kirk Clark

Executive Director, Protein Structure Group, Novartis Institutes for Biomedical Research
Role on Board: Non-directorial member (

Chairman of the SGC Scientific Committee)
Nominating organisation: Novartis

Prof. Aled Edwards

CEO, SGC
Role on Board: Management Team
Nominating organisation: SGC

Dr. Chas Bountra

CSO (Oxford), SGC
Role on Board: Management Team
Nominating organisation: SGC Oxford

Dr. Cheryl Arrowsmith

CSO (Toronto), SGC
Role on Board: Management Team
Nominating organisation: SGC Toronto

Dr. Johan Weigelt

Associate Director, SGC
Role on Board: Management Team
Nominating organisation: SGC

Dr. Meher Antia

Science Portfolio Adviser, Wellcome Trust
Role on Board: Secretary
Nominating organisation: Independent